Ipca Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Ipca Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 30.3% bzw. 12.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 30.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.9% betragen.

Wichtige Informationen

30.3%

Wachstumsrate der Gewinne

30.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum18.3%
Wachstumsrate der Einnahmen12.1%
Zukünftige Eigenkapitalrendite14.9%
Analystenabdeckung

Good

Zuletzt aktualisiert19 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Sep 20
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Aug 31
Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Jun 22
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

May 28
Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Mar 15
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20
These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26
How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13
Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28
Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23
Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11
Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30
Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15
The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Dec 31
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Dec 16
Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Gewinn- und Umsatzwachstumsprognosen

NSEI:IPCALAB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
3/31/2027114,34614,22810,964N/A12
3/31/2026102,59911,7318,892N/A17
3/31/202590,1238,8987,865N/A17
6/30/202482,1335,768N/AN/AN/A
3/31/202477,0595,4745,3419,447N/A
12/31/202371,8755,643N/AN/AN/A
9/30/202366,8064,9222,6126,767N/A
6/30/202362,5004,911N/AN/AN/A
3/31/202362,4814,7133,1138,058N/A
12/31/202260,2255,250N/AN/AN/A
9/30/202259,0706,1422,3987,616N/A
6/30/202258,5057,205N/AN/AN/A
3/31/202258,3058,8413,7718,561N/A
12/31/202156,5619,152N/AN/AN/A
9/30/202156,3559,8373,7288,554N/A
6/30/202154,52110,005N/AN/AN/A
3/31/202154,20711,4007,28610,901N/A
12/31/202053,80210,647N/AN/AN/A
9/30/202051,8339,9687,37110,767N/A
6/30/202051,0619,228N/AN/AN/A
3/31/202046,4996,0632,6415,704N/A
12/31/201944,5636,189N/AN/AN/A
9/30/201942,4965,8042,8775,181N/A
6/30/201939,7775,059N/AN/AN/A
3/31/201937,7504,4483,2055,010N/A
3/31/201832,8522,394N/A3,411N/A
3/31/201731,5621,945N/A2,819N/A
3/31/201628,671931N/A7,087N/A
3/31/201531,4442,542N/A4,682N/A
3/31/201432,8184,785N/A5,223N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IPCALABDas prognostizierte Gewinnwachstum (30.3% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: IPCALABDie Erträge des Unternehmens (30.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (18.1% pro Jahr).

Hohe Wachstumserträge: IPCALABEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: IPCALABDie Einnahmen des Unternehmens (12.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.2% pro Jahr).

Hohe Wachstumseinnahmen: IPCALABDie Einnahmen des Unternehmens (12.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IPCALABDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.9%).


Wachstumsunternehmen entdecken